Adhera Therapeutics Inc (ATRX PINK) stock market data APIs
$0
0(0%)
as of April 24, 2025
Adhera Therapeutics Inc Financial Data Overview
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Prev. Close
0
Open
0
High
0
Low
0
52 wk Range
0.0001-0.017
Market Cap
722
Shares Outstanding
7 221 K
Revenue
132 K
EPS
-0.8278
Beta
3.511
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adhera Therapeutics Inc data using free add-ons & libraries
Get Adhera Therapeutics Inc Fundamental Data
Adhera Therapeutics Inc Fundamental data includes:
- Net Revenue: 132 K
- EBITDA: -1 955 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-11-22
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adhera Therapeutics Inc News
New
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidateCompany moving forward with application to transition from OTC to NASDAQ Baton...
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September...
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company h...
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointm...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
